Featuring an interview with Prof Karim Fizazi, including the following topics:

• Perspectives on the PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy for high-risk localized prostate cancer (0:00)
• Mechanism of action of opevesostat and potential role in castration-resistant prostate cancer with androgen receptor mutations (15:37)
• Perspectives on alpha- and beta-emitting radiopharmaceuticals in the treatment of prostate cancer (22:47)
• Novel antibody-drug conjugates and proteolysis-targeting chimeras (30:43)
• Treatment approaches for metastatic hormone-sensitive prostate cancer — de novo symptomatic presentation versus PSMA-only metastatic recurrence after local therapy (34:51)
• Role of intermittent therapy in the treatment of prostate cancer (38:48)
• Treatment intensification approaches in prostate cancer (41:38)
• Case: A man in his late 60s with de novo PSMA PET-positive metastatic castration-sensitive prostate cancer (45:25)

CME information and select publications

Featuring an interview with Dr Neeraj Agarwal, including the following topics:

• Impact of PTEN deficiency on PI3K/AKT/mTOR pathway; optimal approaches to testing (0:00)
• Approaches to monitoring for disease progression in patients who are PTEN deficient; prognostic significance and implications for testing (7:13)
• Potential usage of capivasertib as second-line therapy for metastatic androgen pathway modulation-naïve/-sensitive (APMN/S) prostate cancer (15:15)
• Managing treatment-related adverse events from capivasertib (20:08)
• Case: A man in his late 50s diagnosed with metastatic APMS prostate cancer and a PTEN deficiency who receives capivasertib (29:17)
• Case: A man in his late 70s diagnosed with high-volume metastatic APMN prostate cancer and a PTEN deficiency who experiences disease progression on androgen deprivation therapy and enzalutamide (40:39)

CME information and select publications

Featuring perspectives from Dr Alexandra Drakaki, including the following topics:

• Case: A man in his late 70s with diabetes and metastatic bladder cancer achieves radiographic response with enfortumab vedotin (EV) and pembrolizumab but develops uncontrolled hyperglycemia (0:00)
• Case: A man in his early 70s with muscle-invasive bladder cancer receives adjuvant nivolumab and experiences metastatic progression after 9 cycles of therapy (6:23)
• Case: A woman in her early 70s with Lynch syndrome and metastatic upper tract bladder cancer receives EV/pembrolizumab and develops myasthenia gravis (13:59)
• Case: A woman in her late 40s with FGFR3 mutant metastatic bladder cancer receives erdafitinib and experiences rising serum phosphate levels (20:04)

CME information and select publications

Featuring perspectives from Dr Alexandra Drakaki, including the following topics:

• Case: A man in his early 80s with bladder cancer and metastatic progression in the viscera and lymph nodes receives enfortumab vedotin (EV) with pembrolizumab — Part 1 (0:00)
• Case: A man in his early 80s with metastatic bladder cancer achieves a complete response with EV/pembrolizumab therapy but develops gastrointestinal toxicity — Part 2 (5:37)
• Case: A man in his early 50s with metastatic bladder cancer receives second-line EV monotherapy intermittently (15:09)
• Case: A woman in her mid 60s with bladder cancer and a history of rheumatoid arthritis develops oligometastatic progression in the lung and receives EV monotherapy (21:03)
• Case: A man in his mid 80s with HER2-positive (IHC 3+) metastatic bladder cancer receives trastuzumab deruxtecan and develops ground glass opacities in his lungs concerning for pneumonitis (30:43)

CME information and select publications

Featuring perspectives from Dr William K Oh and Dr Mary-Ellen Taplin, including the following topics:

• Introduction: Another Perspective on the Treatment of Localized Prostate Cancer (0:00)
• Nonmetastatic Disease (10:32)
• Metastatic Androgen Pathway Modulation-Naïve and Androgen Pathway Modulation-Sensitive Disease (41:50)

CME information and select publications

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:

• Tolerability of capivasertib and management of associated side effects — Question from Neeraj Agarwal, MD, FASCO (0:00)
• Case: A man in his early 70s with Type 2 diabetes presents with metastatic hormone-sensitive prostate cancer with widespread bone metastases and PTEN deficiency on next-generation sequencing and receives relugolix/darolutamide — Rana R McKay, MD, FASCO (8:39)

CME information and select publications

Featuring perspectives from Mr Michael Lai, Dr Scott T Tagawa, Ms Stacy E Walker and Dr Evan Y Yu, moderated by Dr Tagawa, including the following topics:

• Introduction (0:00)
• Overview of Prostate Cancer (3:00)
• Hormonal Therapy for Nonmetastatic and Metastatic Hormone-Sensitive Prostate Cancer (HSPC) (6:12)
• Potential Role of Capivasertib in Metastatic HSPC (27:22)
• Current and Potential Future Role of PARP Inhibitors in Metastatic PC (46:39)
• Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic PC (1:09:14)

CME information and select publications

Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:

• Case: A patient with T4 disease, pelvic wall involvement and a positive pelvic node treated as metastatic disease with enfortumab vedotin and pembrolizumab attains a complete response on imaging after 6 cycles (0:00)
• Case: A man with muscle-invasive bladder cancer who receives neoadjuvant chemotherapy with durvalumab receives positive circulating tumor DNA results before cystectomy and negative results after surgery (7:41)

CME information and select publications